The pooled incidence of cancer therapy-related cardiac dysfunction in adults receiving cancer therapy was 27% (95% CI 0.20-0.35).
Meta-Analysis (n=2,083)
What is the incidence of cancer therapy-related cardiac dysfunction and the utility of serial GLS and LVEF monitoring in adults receiving cancer therapy?
CTRCD occurs in approximately 27% of patients receiving cancer therapy, and serial monitoring shows that GLS deterioration precedes LVEF decline, supporting its use in surveillance.
Objective: To estimate the pooled incidence of cancer therapy-related cardiac dysfunction (CTRCD), assess longitudinal changes in global longitudinal strain (GLS) and left ventricular ejection fraction (LVEF), and summarise the available evidence comparing echocardiography and cardiac magnetic resonance (CMR) for serial functional assessment. Methods: We performed a systematic review and meta-analysis of observational studies reporting CTRCD in adults receiving cancer therapy. Pooled CTRCD incidence was estimated, study-level meta-regression explored associations between baseline mean GLS and LVEF and CTRCD event rates, and longitudinal changes in GLS and LVEF were compared between CTRCD and non-CTRCD cohorts across follow-up visits. Exploratory subgroup analyses compared findings derived from echocardiography and CMR. Results: Thirty-three studies were included (total enrolled n = 2083; analysed at follow-up n = 1973), including 27 echocardiography-only studies, 4 CMR-only studies, and 2 studies reporting both modalities at baseline. The pooled incidence of CTRCD was 27% (95% CI 0.20–0.35), with substantial heterogeneity across studies. In study-level meta-regression, baseline mean GLS (p = 0.195) and baseline mean LVEF (p = 0.668) were not significantly associated with CTRCD event rates. Compared with non-CTRCD cohorts, CTRCD cohorts showed greater worsening in GLS across all analysed follow-up intervals. Within CTRCD cohorts, both GLS and LVEF deteriorated over time, whereas non-CTRCD cohorts showed smaller changes overall. Exploratory subgroup analyses did not detect statistically significant differences between echocardiography and CMR in the available datasets. Conclusions: CTRCD is reported in approximately one-quarter of patients across published studies, although estimates vary substantially by population, therapy, follow-up schedule, and CTRCD definition. Longitudinal deterioration in GLS appears earlier and more consistently than decline in LVEF, supporting the role of serial deformation imaging in surveillance. Baseline study-level mean GLS and LVEF were not significantly associated with CTRCD event rates, and direct comparative evidence between echocardiography and CMR remains limited.
Altamimi et al. (Thu,) conducted a meta-analysis in Cancer therapy-related cardiac dysfunction (CTRCD) (n=2,083). Cancer therapy was evaluated on Pooled incidence of cancer therapy-related cardiac dysfunction (CTRCD) (95% CI 0.20-0.35). The pooled incidence of cancer therapy-related cardiac dysfunction in adults receiving cancer therapy was 27% (95% CI 0.20-0.35).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: